- Home
- IBO vs CMND Comparison
IBO vs CMND Comparison
Compare IBO & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBO
- CMND
- Stock Information
- Founded
- IBO 2018
- CMND 2017
- Country
- IBO United States
- CMND Canada
- Employees
- IBO N/A
- CMND N/A
- Industry
- IBO
- CMND Biotechnology: Pharmaceutical Preparations
- Sector
- IBO
- CMND Health Care
- Exchange
- IBO NYSE
- CMND Nasdaq
- Market Cap
- IBO 5.8M
- CMND 4.8M
- IPO Year
- IBO 2024
- CMND N/A
- Fundamental
- Price
- IBO $0.76
- CMND $0.85
- Analyst Decision
- IBO
- CMND
- Analyst Count
- IBO 0
- CMND 0
- Target Price
- IBO N/A
- CMND N/A
- AVG Volume (30 Days)
- IBO 23.2M
- CMND 122.4K
- Earning Date
- IBO 08-23-2025
- CMND 06-12-2025
- Dividend Yield
- IBO N/A
- CMND N/A
- EPS Growth
- IBO N/A
- CMND N/A
- EPS
- IBO N/A
- CMND N/A
- Revenue
- IBO N/A
- CMND N/A
- Revenue This Year
- IBO N/A
- CMND N/A
- Revenue Next Year
- IBO N/A
- CMND N/A
- P/E Ratio
- IBO N/A
- CMND N/A
- Revenue Growth
- IBO N/A
- CMND N/A
- 52 Week Low
- IBO $0.36
- CMND $0.80
- 52 Week High
- IBO $6.17
- CMND $2.30
- Technical
- Relative Strength Index (RSI)
- IBO N/A
- CMND 41.60
- Support Level
- IBO N/A
- CMND $0.83
- Resistance Level
- IBO N/A
- CMND $0.93
- Average True Range (ATR)
- IBO 0.00
- CMND 0.06
- MACD
- IBO 0.00
- CMND 0.00
- Stochastic Oscillator
- IBO 0.00
- CMND 32.64
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.